biotricity which uses cardiocoms fda cleared technology is uo 47% todayToronto, Ontario, Oct 22, 2018 (Newsfile Corp via COMTEX) -- CardioComm Solutions, Inc. (EKG) ("CardioComm" or the "Company"), a leading global provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions confirmed today progress on a royalty licencing agreement with Redwood City, California-based Biotricty Inc. ("Biotricity"). The royalty payment phase became active following confirmation that all necessary clearance and software development pre-conditions have been achieved.